// App-Quantinova.ai

: CLINICAL SIGNIFICANCE OF MPL MUTATIONS IN ESSENTIAL THROMBOCYTEMIA PATIENTS: RISK ASSESMENT OF MYELOFIBROTIC TRANSFORMATION.

Researchers

Presenter

  • Roco Garca-Serra

Principal Investigators

  • Marisol Uribe

  • Sofa Costa

  • Karla Javier

  • Mara Marn

  • Patricia Lpez

  • Maria Josefa Lis

  • Maria Teresa Orero

  • Fernando Hernndez

  • Mara Lpez-Pava

  • Mnica Roig

  • Pedro Luis Prez

  • Armando Mena

  • Francisco Ibez

  • Elena Vidal

  • Mariano Linares

  • Antonio Cerver

  • Rosa Collado

Medical Centers

  • Hematology,Fundación Hospital General Universitario de Valencia,Valencia,Spain;Hematology,Hospital General Universitario de Valencia,Valencia,Spain

  • Consorcio Hospital General Universitario de Valencia, Valencia, Spain

  • Hematology,Hospital Virgen de los Lirios,Alcoy,Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

  • Endocrine/metabolic Diseases (ME)

  • Oncology (ONC)

Disease

  • Diabetes

  • Acute Leukemia

  • Hypertension

  • Venous thrombosis

Biomarkers

  • MPL proto-oncogene, thrombopoietin receptor

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved